| Autor: |
Stinkens K; Department of Endocrinology UZ Leuven, UZ Gasthuisberg, Leuven, Belgium., Mathieu C; Department of Endocrinology UZ Leuven, UZ Gasthuisberg, Leuven, Belgium. |
| Jazyk: |
angličtina |
| Zdroj: |
European endocrinology [Eur Endocrinol] 2016 Mar; Vol. 12 (1), pp. 33-34. Date of Electronic Publication: 2016 Mar 15. |
| DOI: |
10.17925/EE.2016.12.01.33 |
| Abstrakt: |
The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
